Phosphodiesterase (PDE10) Targeted Library

Phosphodiesterases (PDE) are a family of enzymes that degrade the phosphodiester bond in the second messenger molecules, cAMP and cGMP, to terminate signal transduction. PDE10, a dual cAMP/cGMP phosphodiesterase, is expressed at high levels in the striatal medium spiny neurons, but elsewhere in the brain and other tissues, it is expressed at very low levels. Therefore, it is an attractive target for effective and selective treatment of degenerative CNS disorders. Inhibitors of phosphodiesterase PDE10 may potentially cure psychiatric and neurological diseases, including schizophrenia, delusional disorder, anxiety disorders, Alzheimer’s disease, movement disorders such as Parkinson’s and Huntington’s diseases. Cognitive dysfunction is responsible for substantial disability in most of these diseases and is not improved significantly by current medications.

Life Chemicals has designed its original Phosphodiesterase Screening Library by combining different computational approaches to develop a unique method for in silico search of screening compounds with potential PDE10 inhibitory activity.

At the first stage, a general 3D pharmacophore model was created based on the structure of the three most potent PDE10 inhibitors (Fig. 1). The model was validated, using a reference set of 150 active and 10 non-active compounds (ChEMBL DB). TopomerSearch tool implemented in the SYBYL-X was used for effective and quick selection of potentially active molecules based on pharmacophore definition. At the next step, the structure of the binding site of PDE10, including water molecules, was modeled. Protein structures recorded in 3UI7, 3UUO, and 4BBX PDB entries were filled with water molecules and optimized using a series of molecular dynamics simulations (GROMACS). The most stable protein structure during calculations was used for docking. A grid model of the PDE10 binding site was created based on features of both key amino acids and a co-crystalized ligand (Glide, Schrödinger). Docking constraints were determined and optimized, using a reference set of molecules with known activities. The scoring rates were brought into conformity to in vitro inhibitory data.

Finally, over 400 small-molecule screening compoundswere selected as potential phosphodiesterase PDE10 inhibitors from the Life Chemicals HTS Compound Collection with the created pharmacophore model (Fig. 2).

Please, contact us at orders@lifechemicals.com for details and quotations.

Figure 1. Pharmacophore model obtained from superposition of three potent PDE 10 inhibitors CHEMBL562317, CHEMBL1939782, and CHEMBL263642.

Figure 1. Pharmacophore model obtained from superposition of three potent PDE 10 inhibitors CHEMBL562317, CHEMBL1939782, and CHEMBL263642.

Example of the binding mode of a hit molecule (left) and some hit structures obtained after docking (right).

Figure 2. Example of the binding mode of a hit molecule (left) and some hit structures obtained after docking (right).

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. By using our website, you accept our conditions of use of cookies to track data and create content (including advertising) based on your interest. Accept